699500 | Kdo2-Lipid A (KLA)

Di[3-deoxy-D-manno-octulosonyl]-lipid A (ammonium salt)


Powder

Size SKU Packaging Price
1mg 699500P-1mg 699500P-1mg $259.37
Base Price: ${originalprice|money}
Custom Packaging: (${concentration} @$4.00/ea. + $100) ${custompackagingtotal|money}
Packaging: ${concentration}
Item Total: ${totalprice|money}
(Sales Tax may apply)
Please select an option above.
${sku} - ${concentration}

Kdo2-Lipid A (KLA)

Kdo2-Lipid A (KLA)

Di[3-deoxy-D-manno-octulosonyl]-lipid A (ammonium salt)

A new preparation of the saccharolipid glycan, Kdo2-Lipid A (KLA), is a nearly homogeneous Re lipopolysaccharide (LPS) substructure with endotoxin activity equal to that of native LPS. KLA is comparable to LPS and its activity is reduced by >103 in cells from TLR-4 deficient mice. The advantage of KLA over LPS is that it is a reproducible, defined natural product, and it can be detected by ESI/MS at the low concentrations used to stimulate animal cells. The purity of KLA should also facilitate the structural analysis of its complexes with signaling receptors, such as TLR-4/MD2.

New research* shows 1μg KLA induces

the same response as 10μg LPS.

Perform experiments at half the cost of using LPS!

 
* Saito, O., C.I. Svensson, M.W. Buczynski, K. Wegner, X.Y. Hua, S. Codeluppi, R.H. Schaloske, R.A. Deems, E.A. Dennis, and T.L. Yaksh. (2010). Spinal glial TLR4-mediated nociception and production of prostaglandin E and TNF. Br J Pharmacol 160:1754-64.
For a list of cell and solution protocols utilizing KLA, please see information on the LIPID MAPS website at the following link.
Hygroscopic
No
Light Sensitive
No
Purity
>95%
Stability
1 Year
Storage Temperature
-20°C
CAS Number
1246298-62-3
CAS Registry Number is a Registered Trademark of the American Chemical Society
Formula Weight
2306.840
Exact Mass
0.000
Synonyms
KLA

Nakayama Y, Fujiu K, Yuki R, Oishi Y, Morioka MS, Isagawa T, Matsuda J, Oshima T, Matsubara T, Sugita J, Kudo F, Kaneda A, Endo Y, Nakayama T, Nagai R, Komuro I, Manabe I. A long noncoding RNA regulates inflammation resolution by mouse macrophages through fatty acid oxidation activation. Proc Natl Acad Sci U S A. 2020 Jun 23;117(25):14365-14375. doi: 10.1073/pnas.2005924117. Epub 2020 Jun 8. PMID: 32513690; PMCID: PMC7322040.

PubMed ID: 32513690

Liebergall SR, Angdisen J, Chan SH, Chang Y, Osborne TF, Koeppel AF, Turner SD, Schulman IG. Inflammation Triggers Liver X Receptor-Dependent Lipogenesis. Mol Cell Biol. 2020 Jan 3;40(2):e00364-19. doi: 10.1128/MCB.00364-19. PMID: 31658997; PMCID: PMC6944475.

PubMed ID: 31658997

Gottschalk RA, Dorrington MG, Dutta B, Krauss KS, Martins AJ, Uderhardt S, Chan W, Tsang JS, Torabi-Parizi P, Fraser ID, Germain RN. IFN-mediated negative feedback supports bacteria class-specific macrophage inflammatory responses. Elife. 2019 Aug 6;8. pii: e46836. doi: 10.7554/eLife.46836.

PubMed ID: 31385572

Quiroga IY, Pellon-Maison M, Suchanek AL, Coleman RA, Gonzalez-Baro MR. Glycerol-3-phosphate acyltransferases 3 and 4 direct glycerolipid synthesis and affect functionality in activated macrophages. Biochem J. 2019 Jan 11;476(1):85-99. doi: 10.1042/BCJ20180381.

PubMed ID: 30523059

Raetz, C.R., Garrett, T.A., Reynolds, C.M., Shaw, W.A., Moore, J.D., Smith, D.C., Jr, Ribeiro, A.A., Murphy, R.C., Ulevitch, R.J., Fearns, C., Reichart, D., Glass, C.K., Benner, C., Subramaniam, S., Harkewicz, R., Bowers-Gentry, R.C., Buczynski, M.W., Cooper, J.A., Deems, R.A., Dennis, E.A. (2006) Kdo2-Lipid A of Escherichia coli, a defined endotoxin that activates macrophages via TLR-4. J Lipid Res. 47:1097-111.

PubMed ID: 16479018

Allegood, J.,Wang, E.,Sullards, M.C.,Merrill, A.H., Jr. (2007)Quantitative analysis of sulfatides in RAW 264.7 cells treated with Kdo2-Lipid A. FASEB J. 21:779.12.


Wei, J., Wang, E., Kelly, S.,Sullards, C.,Merrill, A. (2007)Up-regulation of de novo sphingolipid biosynthesis through serine palmitoyltransferease in RAW 264.7 cells upon Kdo2-Lipid A treatment. FASEB J. 21:487.11


Sasaki, H., White, S.H. (2008)Aggregation behavior of an ultra-pure lipopolysaccharide that stimulates TLR-4 receptors. Biophys J. 95:986-93.

PubMed ID: 18375521

Saito, O., Svensson, C.I., Buczynski, M.W., Wegner, K., Hua, X.-Y., Codeluppi, S., Schaloske, R.H., Deems, R.A., Dennis, E.A., Yaksh, T.L. (2010) Spinal glial TLR4-mediated nociception and production of prostaglandin E2 and TNF. British Journal of Pharmacology 160:1754–1764.


Chung, H.S. and C.R. Raetz. (2010). Interchangeable domains in the Kdo transferases of Escherichia coli and Haemophilus influenzae. Biochemistry 49:4126-37.

PubMed ID: 20394418

Andreyev, A.Y., Fahy, E., Guan, Z., Kelly, S., Li, X., McDonald, J.G., Milne, S., Myers, D., Park, H., Ryan, A., Thompson, B.M., Wang, E., Zhao, Y., Brown, H.A., Merrill, A.H., Raetz, C.R., Russell, D.W., Subramaniam, S., Dennis, E.A. (2010) Subcellular organelle lipidomics in TLR-4-activated macrophages. J Lipid Res. 51:2785-97.

PubMed ID: 20574076
Packaging for animal studies available. Please contact technical@avantilipids.com.
References:
Gu, B.B., J.F. Miao, Y.M. Zhu, Y.E. Deng, and S.X. Zou. (2009). Protective effect of retinoid against endotoxin-induced mastitis in rats. Inflamm Res 58:81-8. Yajima, S., H. Morisaki, R. Serita, T. Suzuki, N. Katori, T. Asahara, K. Nomoto, F. Kobayashi, A. Ishizaka, and J. Takeda. (2009). Tumor necrosis factor-alpha mediates hyperglycemia-augmented gut barrier dysfunction in endotoxemia. Crit Care Med 37:1024-30. Nacira, S., F. Meziani, O. Dessebe, V. Cattan, S. Collin, C. Montemont, S. Gibot, P. Asfar, A. Ramaroson, V. Regnault, M. Slama, T. Lecompte, P. Lacolley, and B. Levy. (2009). Activated protein C improves lipopolysaccharide-induced cardiovascular dysfunction by decreasing tissular inflammation and oxidative stress. Crit Care Med 37:246-55.